In short
Back in February we announced the acquisition of catheter company Navilyst Medical by Angiodynamics. Now the company has announced its entry into the embolisation market with the U.S. launch of its new Embarc® Microcatheter with Glyce™ Hydrophilic Coating.
The new catheter is designed for use in small vessels and what the announcement calls superselective anatomy during diagnostic and interventional procedures in the peripheral vasculature. The company claims it is the first to offer a 1000 psi pressure rating across its entire line of microcatheters.
Background
For the clinician accessing the body’s distal vasculature, the delivery catheter is the single most important component. Kink resistance when advancing and placing a microcatheter is a critical part of its performance.
The Embarc Microcatheter’s braided shaft construction and engineered tapered extrusion are designed to provide kink resistance at the hub, along the shaft and at the tip. Furthermore, this construction allows proximal advancement and optimal stability in embolic delivery and power injection while providing distal flexibility to navigate through tortuous anatomy. The ultra-durable GLYCE™ Hydrophilic Coating on the catheter’s outside surface increases trackability while an extruded PTFE liner affords smooth guidewire and embolic interface. Additional features include a formed distal tip designed for atraumatic advancement and swaged RO marker providing visibility under fluoroscopy and dimensional control for navigation in vessel selection.
Company comments
“The Peripheral Embolization space is an exciting and growing area offering the opportunity for improved outcomes across a wide range of procedures, many of which once required surgery and can now be treated less invasively with less risk, pain and recovery time for the patient,” commented Ron Sparks, Chariman and CEO. “Continuing to make advancements in the devices used by Interventional Radiologists, in what is expected to surpass 140,000 procedures this year alone, is a critical part of improving patient outcomes.”
Source: Navilyst Medical
published: May 7, 2012 in: Launches / Withdrawals, Vascular